Phelix: a testis-specific protein expressed in cancer
CA 2340592 A1 · Owner: Agensys, Inc. · Inventors: Afar, Daniel E.; Raitano, Arthur B.; Hubert, Rene S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described is a novel gene and its encoded basic Helix Loop Helix protein termed PHELIX, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express PHELIX particularly , including prostate cancer bladder cancer, ovarian cancer and testicular cancer. In human normal tissues, PHELIX is only expressed in testis tissue. However, PHELIX is expressed at high levels in prostate cancer cells and in other cancer cells. The structure of PHELIX suggests that it may function as a transcription factor that normally exhibits a testis-specific expression pattern but is turned on in prostate cancer as well as in other cancers.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 31, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 31, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 31, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.